Forest looks to evergreen Namenda through Adamas deal for fixed-dose donepezil combo
This article was originally published in Scrip
Forest Laboratories has paid $65 million up front to license Adamas Pharmaceuticals' proprietary fixed-dose combination (FDC) of memantine and donepezil in the US, giving Forest an opportunity to extend the life of its Namenda (memantine hydrochloride) franchise in moderate-to-severe dementia associated with Alzheimer's disease.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.